Nine More States Offer Medicaid Coverage for Breast and Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

WASHINGTON-Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

WASHINGTON—Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000. 

Alabama, Georgia, Iowa, Mississippi, Missouri, North Dakota, South Carolina, Virginia, and Washington join 19 previously approved states.

Articles in this issue
High-Dose IL-2 Is Standard in Advanced Renal Cell Cancer
RIT Safe, Effective in Elderly and Poor-Prognosis Patients
FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancer
ODAC Recommends Approval of Radiolabeled Zevalin
Proteomics Moves From the Laboratory to Clinical Research
Radiotherapy Not Needed in Older Lumpectomy Patients With Early Cancer
Raltitrexed + Oxaliplatin for Advanced Colorectal Cancer
Mental Fatigue Worries Chemotherapy Patients
Patients Urged to Work With Professionals Against Fatigue
NCI Director Resigns to Head New Scientific Institute
Combined PET/CT Aids in Head and Neck Cancer Management
MRI Method Predicts Early Response
New Cellular Target Shows Promise in Cancer Treatment
ACR Protests Proposed Diagnostic Mammography Reimbursement Rates
High-Volume Hospitals Better for Some Cancer Surgeries
Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

Russ Conroy
October 15th 2024
Article

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

Michael Ganio, PharmD, MS, BCPS, FASHP;Brian Slomovitz, MD;Lucio Gordan, MD
September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Laura Bucher-Bailey, PharmD
September 25th 2024
Article

Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Ariana Pelosci;Gina Mauro
September 20th 2024
Article

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.